Cingulate (CINGW) Cash from Financing Activities (2021 - 2025)
Cingulate's (CINGW) quarterly Cash from Financing Activities came in at $8.6 million in Q4 2025, up 33.17% on a YoY basis from $6.4 million in Q4 2024, and up 487.07% quarter-over-quarter from $1.5 million in Q3 2025.
Analysis
Cingulate (CINGW) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Cingulate (CINGW) has reported Cash from Financing Activities for 5 consecutive years, with $8.6 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 33.17% year-over-year to $8.6 million; the trailing twelve-month figure through Dec 2025 stood at $16.1 million (down 47.6% YoY), and the FY2025 full-year result was $16.1 million, down 47.6% from the prior year.
- Cash from Financing Activities climbed to $8.6 million in Q4 2025 per CINGW's latest filing, from $1.5 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $19.9 million in Q4 2021 and bottomed at -$89780.0 in Q4 2022.
- Historically, Cash from Financing Activities has averaged $4.4 million across 5 years, with a median of $2.6 million in 2023.
- The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 100.45% in 2022, then soared 252377.63% in 2024.
- Over 5 years, Cash from Financing Activities stood at $19.9 million in 2021, then slumped by 100.45% to -$89780.0 in 2022, then soared by 1008.26% to $815434.0 in 2023, then jumped by 690.89% to $6.4 million in 2024, then jumped by 33.17% to $8.6 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $8.6 million, $1.5 million, and $4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.24 Bn | 625.48 Bn | 17.26 Bn | -8.78 Bn |
| 2 | AbbVie | 441.52 Bn | 434.96 Bn | 12.70 Bn | -5.05 Bn |
| 3 | Merck | 365.75 Bn | 358.60 Bn | 12.21 Bn | 1.76 Bn |
| 4 | Novartis Ag | 266.61 Bn | 258.92 Bn | 11.24 Bn | -2.02 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn | -3.66 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn | -2.10 Bn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 2.42 Bn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 65.46 Mn |
| 9 | United Therapeutics | 21.43 Bn | 18.77 Bn | 683.80 Mn | 122.40 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 8.59 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Jun 30, 2025 | 4.18 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Sep 30, 2024 | 13.40 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 9.89 Mn |
| Dec 31, 2023 | 815,434.00 |
| Sep 30, 2023 | 5.93 Mn |
| Jun 30, 2023 | 3.21 Mn |
| Mar 31, 2023 | -3,920.00 |
| Dec 31, 2022 | -89,780.00 |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | -3,745.00 |
| Mar 31, 2022 | -3,682.00 |
| Dec 31, 2021 | 19.91 Mn |
| Sep 30, 2021 | 3.47 Mn |
| Jun 30, 2021 | 1.81 Mn |
| Mar 31, 2021 | 1.35 Mn |